AU2021284297A1 - Antagonistic biparatopic antibodies that specifically bind fibroblast growth factor receptor 2 and methods of using same - Google Patents

Antagonistic biparatopic antibodies that specifically bind fibroblast growth factor receptor 2 and methods of using same Download PDF

Info

Publication number
AU2021284297A1
AU2021284297A1 AU2021284297A AU2021284297A AU2021284297A1 AU 2021284297 A1 AU2021284297 A1 AU 2021284297A1 AU 2021284297 A AU2021284297 A AU 2021284297A AU 2021284297 A AU2021284297 A AU 2021284297A AU 2021284297 A1 AU2021284297 A1 AU 2021284297A1
Authority
AU
Australia
Prior art keywords
antibody
fgfr2
polypeptide
antigen binding
gal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021284297A
Other languages
English (en)
Inventor
Saireudee Chaturantabut
William Sellers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Broad Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Broad Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc, Broad Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2021284297A1 publication Critical patent/AU2021284297A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021284297A 2020-06-03 2021-06-02 Antagonistic biparatopic antibodies that specifically bind fibroblast growth factor receptor 2 and methods of using same Pending AU2021284297A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063033975P 2020-06-03 2020-06-03
US63/033,975 2020-06-03
PCT/US2021/035468 WO2021247718A1 (en) 2020-06-03 2021-06-02 Antagonistic biparatopic antibodies that specifically bind fibroblast growth factor receptor 2 and methods of using same

Publications (1)

Publication Number Publication Date
AU2021284297A1 true AU2021284297A1 (en) 2023-02-02

Family

ID=78829919

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021284297A Pending AU2021284297A1 (en) 2020-06-03 2021-06-02 Antagonistic biparatopic antibodies that specifically bind fibroblast growth factor receptor 2 and methods of using same

Country Status (7)

Country Link
US (1) US20230295308A1 (https=)
EP (1) EP4161566A4 (https=)
JP (1) JP2023528454A (https=)
CN (1) CN116367855A (https=)
AU (1) AU2021284297A1 (https=)
CA (1) CA3185812A1 (https=)
WO (1) WO2021247718A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250148746A (ko) * 2023-01-13 2025-10-14 리제너론 파아마슈티컬스, 인크. Fgfr3 결합 분자 및 그의 사용 방법
CN118852431A (zh) * 2023-04-28 2024-10-29 武汉人福创新药物研发中心有限公司 抗FGFR2b单抗
WO2025070733A1 (en) * 2023-09-29 2025-04-03 Chugai Seiyaku Kabushiki Kaisha Anti-rtk antibodies and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2083081A1 (en) * 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
HUE035700T2 (en) * 2008-11-07 2018-05-28 Galaxy Biotech Llc Monoclonal antibodies to Fibroblast Growth Factor receptor 2
AR088941A1 (es) * 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
US9498532B2 (en) * 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
AU2014357292B2 (en) * 2013-11-27 2020-06-25 Zymeworks Bc Inc. Bispecific antigen-binding constructs targeting HER2
CA2961439A1 (en) * 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
CN107446045A (zh) * 2016-07-22 2017-12-08 北京天广实生物技术股份有限公司 一种抗her2的抗体、其药物组合物及用途
MX2019005552A (es) * 2016-11-14 2019-08-12 Amgen Inc Proteinas de union a antigenos biespecificas o biparatopicas y usos de las mismas.

Also Published As

Publication number Publication date
EP4161566A1 (en) 2023-04-12
CA3185812A1 (en) 2021-12-09
US20230295308A1 (en) 2023-09-21
WO2021247718A1 (en) 2021-12-09
JP2023528454A (ja) 2023-07-04
CN116367855A (zh) 2023-06-30
EP4161566A4 (en) 2024-06-12

Similar Documents

Publication Publication Date Title
CN111683970B (zh) C-kit结合剂
JP2022036957A (ja) Ｓｉｒｐポリペプチド組成物および使用の方法
JP2022536898A (ja) 新規ｉｌ－１５プロドラッグおよびその使用方法
WO2020020281A1 (zh) 抗tigit抗体及其用途
KR20220121850A (ko) 항-cd73 항체 및 이의 용도
JP2020018298A (ja) Ｃｌｄｎ１８．２及びｃｄ３に対する抗体コンストラクト
EP3928790A1 (en) Cd3 antigen binding fragment and application thereof
US12509520B2 (en) Anti-CD3 and anti-CD123 bispecific antibody and use thereof
CN107810197B (zh) 鉴定包含结合多肽的细菌的方法
CN107722122A (zh) Vegf/dll4结合剂及其应用
CN102459346A (zh) 制造异源多聚体分子的方法
CN114981301B (zh) Pd1和vegfr2双结合剂
US20230295308A1 (en) Antagonistic biparatopic antibodies that specifically bind fibroblast growth factor receptor 2 and methods of using same
JP2019514871A (ja) 骨髄性白血病の治療方法で使用するための、ｃｄ３３とｃｄ３に結合する二重特異性構築物の投与の方法
KR20240107202A (ko) 항-트랜스페린 수용체 항체 및 이의 용도
WO2019242619A1 (zh) 全人源的抗lag-3抗体及其应用
KR20220087466A (ko) 항-케모킨(anti-chemokin) 유사 수용체 1 사람화된 항체 및 이의 치료학적 적용
IL323270A (en) Antibody against PTK7 and its uses
CN111818972A (zh) 去免疫的抗erbb3抗体
WO2024017326A1 (zh) 抗gprc5d纳米抗体及其应用
WO2015169811A2 (en) Anti-cxc chemokine receptor-2 binding molecules and uses thereof
CN111295395A (zh) 抗体和使用方法
KR20230098335A (ko) 클리핑 비율이 감소된 항원 결합 도메인
TW202423987A (zh) 抗ccr8抗體及其應用
CN119546645A (zh) 特异性结合gucy2c和cd3的抗原结合分子及其医药用途